PLoS ONE (Jan 2020)

Mycobacterium tuberculosis polyclonal infections through treatment and recurrence.

  • Pooja Pandey,
  • Anuj K Bhatnagar,
  • Anant Mohan,
  • Kuldeep S Sachdeva,
  • Jyotish C Samantaray,
  • Randeep Guleria,
  • Urvashi B Singh

DOI
https://doi.org/10.1371/journal.pone.0237345
Journal volume & issue
Vol. 15, no. 8
p. e0237345

Abstract

Read online

BackgroundMixed/polyclonal infections due to different genotypes are reported in Tuberculosis. The current study was designed to understand the fate of mixed infections during the course of treatment and follow-up and its role in disease pathogenesis.MethodsSputum samples were collected on 0,1,2,3,6,12 and 24 months from 157 treatment-naïve patients, cultures subjected to Drug-Susceptibility-testing (MGIT 960), spoligotyping, MIRU-VNTR and SNP genotyping. All isolated colonies on thin layer agar (7H11) were subjected to spoligotyping.FindingsOne thirty three baseline cultures were positive (133/157, 84.7%), 43(32.3%) had mixture of genotypes. Twenty-four of these patients (55.8%) showed change in genotype while six showed different drug-susceptibility patterns while on treatment. Twenty-three (53.5%) patients with polyclonal infections showed resistance to at least one drug compared to 10/90 (11.1%) monoclonal infections (PConclusionsThe coexistence of different genotypes and change of genotypes during the same disease episode, while on treatment, confirms constancy of polyclonal infections. The composition of the mixture of genotypes and the relative predominance may be missed by culture due to its limit of detection. Polyclonal infections in TB could be a rule rather than exception and challenges the age-old dogma of reactivation/reinfection.